Plenary II Session
This session will review the latest science in the field of head and neck cancer.
Target Audience
This meeting was designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the latest science in the field of head and neck cancer.
Speakers
- Siddharth Sheth, DO, MPH, UNC Health, Chapel Hill, North Carolina
- Richard Bell, MD, Providence Cancer Institute Frantz Head and Neck Clinic, Portland, Oregon
- Lova Sun, MD, University of Pennsylvania, Philadelphia
- Zhuosheng Gu, Droplet Biosciences, Cambridge, Massachusetts
- Michael Wotman, MD, MD Anderson Cancer Center, Houston
- James Bates, MD, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta
- Bill Diplas, MD, PhD, Memorial Sloan Kettering Cancer Center
- Kenneth Shung Hu, MD, FASTRO, Department of Radiation Oncology, NYU Langone Health, New York
- Sharif Elguindi, MS, Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.

Facebook
X
LinkedIn
Forward